Press Releases
BioVentrix Achieves 2019 NUB Reimbursement Status 1 in Germany for Revivent TC™ TransCatheter Ventricular Enhancement System
San Ramon, Calif., February 28, 2019 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced a significant reimbursement achievement. InEk, the German Institute for Hospital Remuneration, has reconfirmed the award of NUB Status 1 for the Revivent TC™ TransCatheter Ventricular [...]
BioVentrix Announces First Patient at Cardiovascular Institute of the South Successfully Treated in IDE Study of Revivent TC™ TransCatheter Ventricular Enhancement Treatment
San Ramon, Calif., and Houma, LA,, March 12, 2018 — BioVentrix, Inc., a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced successful treatment of the first patient at the Cardiovascular Institute of the South in the ALIVE pivotal clinical trial. The trial is [...]
BioVentrix Achieves 2018 NUB Reimbursement Status 1 in Germany for Revivent TC™ TransCatheter Ventricular Enhancement System
San Ramon, Calif., February 06, 2018 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced a significant reimbursement achievement. InEk, the German Institute for Hospital Remuneration, has reconfirmed the award of NUB Status 1 for the Revivent TC™ TransCatheter Ventricular [...]
BioVentrix announces the 1st image fusion-guided Revivent TC™ TransCatheter Ventricular Enhancement procedure for treating Ischemic Cardiomyopathy
San Ramon, Calif., and Mainz, Germany, April 17, 2017 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the first image fusion-guided procedure with its Revivent TC system. The procedure, known as Less Invasive Ventricular Enhancement™ or LIVE™, was performed [...]
BioVentrix announces the 1st Revivent TC™ TransCatheter commercial procedure to Treat Ischemic Cardiomyopathy in China
San Ramon, Calif., and Xiamen, China, March 13, 2017 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced commercialization and the first clinical use of its closed-chest Revivent TC™ System in the People’s Republic of China. The Less Invasive Ventricular [...]
BioVentrix Announces NUB Reimbursement Status 1 for Revivent TC™ TransCatheter Ventricular Enhancement System in Germany
San Ramon, Calif., February 6, 2017 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced that InEk, the German Institute for the Hospital Remuneration System, has awarded NUB Status 1 for the Revivent TC™ TransCatheter Ventricular Enhancement System.The NUB process [...]
BioVentrix announces the 1st Revivent TC™ TransCatheter Ventricular Enhancement procedure in Germany after receiving CE-Mark Certification
San Ramon, Calif., and Hamburg, Germany, December 19, 2016 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the first closed-chest Revivent TCTM TransCatheter Ventricular Enhancement System procedure in Germany since receiving CE mark certification. The Less Invasive Ventricular EnhancementTM [...]
BioVentrix announces the 1st Revivent TC™ TransCatheter Ventricular Enhancement procedure for Ischemic Cardiomyopathy treatment in the Netherlands
San Ramon, Calif., and Nieuwegein, The Netherlands, November 21, 2016 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the first clinical use in the Netherlands of its closed-chest Revivent TC™ TransCatheter Ventricular Enhancement System. The Less Invasive Ventricular Enhancement™ [...]
Steven Healy appointed as Chairman of the Board of Directors of BioVentrix, Inc.
SAN RAMON, Calif., October 4, 2016 — BioVentrix, Inc., a pioneer of technologies and procedures for less-invasive treatment of heart failure, today announced that current Board member Steven Healy has been appointed to the position of Chairman of the Board of Directors.Kenneth Miller, President and CEO of BioVentrix said, "We [...]
BioVentrix Receives CE Marking Certification for Revivent TC™, the First Minimally Invasive Heart Failure Treatment to Restore the Left Ventricle
The Revivent TC™ TransCatheter Ventricular Enhancement System enables the treatment and management of patients who suffered a myocardial infarction resulting in left ventricular dysfunction. SAN RAMON, Calif., June 27, 2016 – BioVentrix Inc., an emerging medical device company dedicated to the minimally invasive treatment of heart failure (HF), announced today [...]
BioVentrix receives FDA IDE Approval for its Pivotal Clinical Trial, ALIVE
SAN RAMON, Calif., May 31, 2016 – BioVentrix Inc., an emerging medical device company for less invasive treatment of heart failure (HF), today announced that it has received a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial, named ALIVE (American Less [...]
BioVentrix Announces Successful First-In-Man, Catheter-Based Endovascular Clinical Procedure with Revivent-TC™ System for Heart Failure Treatment
SAN RAMON, Calif., and VILNIUS, Lithuania, May 16, 2016 — BioVentrix, a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF), today announced the first-in-man use of its next generation Revivent-TC™ System with an endovascular catheter-based approach from within the left ventricle. The Less Invasive Ventricular Enhancement™ [...]
